

REVIEW

Phenotype pharmacology of lower urinary tract α_1 -adrenoceptors

A Nishimune, H Yoshiki, J Uwada, ASM Anisuzzaman, H Umada and I Muramatsu

Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, Organization for Life Science Advancement Programs, and Child Development Research Center, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan

Correspondence

Ikunobu Muramatsu, Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine, Eiheiji, Fukui 910-1193, Japan. E-mail: muramatsu@u-fukui.ac.jp

Keywords

α_{1L} -adrenoceptor;
 α_{1A} -adrenoceptor;
benign prostatic hyperplasia (BPH);
stress urinary incontinence (SUI);
lower urinary tract;
phenotype pharmacology

Received

28 October 2010

Revised

20 June 2011

Accepted

28 June 2011

α_1 -Adrenoceptors are involved in numerous physiological functions, including micturition. However, the pharmacological profile of the α_1 -adrenoceptor subtypes remains controversial. Here, we review the literature regarding α_1 -adrenoceptors in the lower urinary tract from the standpoint of α_{1L} phenotype pharmacology. Among three α_1 -adrenoceptor subtypes (α_{1A} , α_{1B} and α_{1D}), α_{1A} -adrenoceptor mRNA is the most abundantly transcribed in the prostate, urethra and bladder neck of many species, including humans. In prostate homogenates or membrane preparations, α_{1A} -adrenoceptors with high affinity for prazosin have been detected as radioligand binding sites. Functional α_1 -adrenoceptors in the prostate, urethra and bladder neck have low affinity for prazosin, suggesting the presence of an atypical α_1 -adrenoceptor phenotype (designated as α_{1L}). The α_{1L} -adrenoceptor occurs as a distinct binding entity from the α_{1A} -adrenoceptor in intact segments of variety of tissues including prostate. Both the α_{1L} - and α_{1A} -adrenoceptors are specifically absent from *Adra1A* (α_{1A}) gene-knockout mice. Transfection of α_{1A} -adrenoceptor cDNA predominantly expresses α_{1A} -phenotype in several cultured cell lines. However, in CHO cells, such transfection expresses α_{1L} - and α_{1A} -phenotypes. Under intact cell conditions, the α_{1L} -phenotype is predominant when co-expressed with the receptor interacting protein, CRELD1 α . In summary, recent pharmacological studies reveal that two distinct α_1 -adrenoceptor phenotypes (α_{1A} and α_{1L}) originate from a single *Adra1A* (α_{1A} -adrenoceptor) gene, but adrenergic contractions in the lower urinary tract are predominantly mediated via the α_{1L} -adrenoceptor. From the standpoint of phenotype pharmacology, it is likely that phenotype-based subtypes such as the α_{1L} -adrenoceptor will become new targets for drug development and pharmacotherapy.

LINKED ARTICLE

This article is commented on by Ventura, pp. 1223–1225 of this issue. To view this commentary visit <http://dx.doi.org/10.1111/j.1476-5381.2011.01663.x>

Abbreviations

BPH, benign prostatic hyperplasia; CRELD1 α , cycteine-rich epidermal growth factor-like domain 1 α ; NS-49 (R)-(-)-3'-(2-amino-1-hydroxyethyl)-4'-fluoromethanesulphonanilide hydrochloride; Ro 115-1240 (Dabuzalgron, R-450), N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl] methanesulphonamide; RS-17053, N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro- α , α -dimethyl-1 *H*-indole-3-ethanamine hydrochloride; silodosin, 1-(3-hydroxypropyl)-5-[(2*R*)-{(2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl)amino} propyl] indoline-7-carboxamide; SUI, stress urinary incontinence; WB4101, 2(N[2,6-dimethoxyphenoxyethyl]amino-methyl-1,4-benzodioxane

Introduction

The lower urinary tract is responsible for urine storage and voiding (Andersson and Wein, 2004). In mammalian species including humans, the bladder detrusor muscle contracts through a parasympathetic cholinergic mechanism during

micturition (Abrams *et al.*, 2006; Wess *et al.*, 2007). Besides the importance of the cholinergic system as the major mechanism for bladder neck muscle tone control, the adrenergic systems play significant roles in the regulation of bladder neck tone (Fig. 1). During the storage phase, the urethra and outlet region of the bladder is contracted to




Figure 1

Autonomic innervation and main functional receptors involved in controlling smooth muscle tension in lower urinary tract tissues. NA, noradrenaline; α_{1L} , α_{1L} -adrenoceptor; β_3 , β_3 -adrenoceptor; M_3 , M_3 -muscarinic acetylcholine receptor.

maintain continence. There is good pharmacological evidence supporting the view that noradrenaline-mediated contraction of the urethral smooth muscle has an important role (Andersson and Wein, 2004).

Among impairments in urine storage, stress urinary incontinence (SUI) is recognized as one of the most frequently occurring conditions. Deficient urethral or bladder neck closure may result in this condition. However, drug treatments for SUI are scarce, at present (Andersson and Wein, 2004). The density of noradrenergic nerves increases markedly towards the bladder neck and urethra (Gosling *et al.*, 1999). α_1 -Adrenoceptors play important roles in both urethral and bladder neck contraction, and may be related to SUI (Andersson and Wein, 2004).

During the voiding phase, prostatic smooth muscle tone contributes to outlet resistance regulation. Benign prostatic hyperplasia (BPH) is a common enlargement of the prostate gland that may lead to bladder outlet obstruction, and lower urinary tract symptoms. BPH is currently recognized as a target for pharmacotherapy utilizing α_1 -adrenoceptor antagonists. In BPH patients, enlargement of the prostate increases bladder outlet resistance and thereby impedes physiological voiding. α_1 -Adrenoceptor antagonists are believed to inhibit contraction of the prostate and urethra, and as a result, α_1 -adrenoceptor antagonists such as tamsulosin, alfuzosin and silodosin effectively reduce resistance to urinary flow and are now clinically used in BPH patients (Lefevre-Borg *et al.*, 1993; Cooper *et al.*, 1999; Ruffolo and Hieble, 1999; Takeda *et al.*, 1999; Chapple, 2001; Andersson, 2002; Michel and Vrydag, 2006).

The functional roles of α_1 -adrenoceptors have been highlighted through the study of their roles in lower urinary tract physiology. These are supported by numerous studies including quantification of mRNAs, anatomical localization of

mRNAs, or of receptors demonstrated by ligand-binding studies (Table 1). On the other hand, functional studies have shown discrepancies between the native α_1 -adrenoceptors found in the lower urinary tract (so-called α_{1L} -adrenoceptor) and the classical α_1 -adrenoceptors (α_{1A} , α_{1B} and α_{1D} ; receptor nomenclature follows Alexander *et al.*, 2011) (Table 2). Subsequent studies revealed the origin of these unique α_1 -adrenoceptors in the lower urinary tract (Ford *et al.*, 1997; Gray *et al.*, 2008; Muramatsu *et al.*, 2008; Nishimune *et al.*, 2010b). In this review, we will introduce recent progress in the study of α_1 -adrenoceptors in the lower urinary tract as an example of the importance of phenotype pharmacology (Kenakin, 2003; Muramatsu *et al.*, 2005; 2008; Nelson and Challiss, 2007; Su *et al.*, 2008).

α_1 -Adrenoceptor mRNAs in the lower urinary tract

Three cDNAs for distinct α_1 -adrenoceptor subtypes (α_{1A} , α_{1B} and α_{1D}) have been cloned, and their pharmacological phenotypes are consistent with pharmacological characteristics of α_1 -adrenoceptors found in many native tissues (Lomasney *et al.*, 1991; Hieble *et al.*, 1995) (Table 2). In the lower urinary tract, the mRNA and protein for these three subtypes have been demonstrated (Table 1) (Michelotti *et al.*, 2000; Michel and Vrydag, 2006; Nishimune *et al.*, 2010a). Among them, the α_{1A} -adrenoceptor mRNA is the most form in the lower urinary tract of many species (Table 1). Data from human studies indicate that the relative abundance ratio of α_{1A} : α_{1B} : α_{1D} -adrenoceptor mRNA is approximately 70:0:30 in the prostate and 90–100:0:0–10 in the urethra (Price *et al.*, 1993; Faure *et al.*, 1994; Nasu *et al.*, 1996; 1998; Michel and Vrydag,

Table 1 α_1 -Adrenoceptor subtypes in lower urinary tract

Tissue	Species	mRNA	Binding	Function
Prostate	Rat	$\alpha_{1a}^{1,2}$	α_{1A}^{12}	$\alpha_{1A}^{12,18,19}$
		$\alpha_{1a}, \alpha_{1b}, \alpha_{1d}^{3-5}$	$\alpha_{1A}, \alpha_{1B}^{13}$	α_{1L}^{13}
	Rabbit	α_{1a}^6	$\alpha_{1A}, \alpha_{1L}^{14}$	α_{1A}^{20-22} $\alpha_{1L}^{14,23-25}$
Urethra	Human	α_{1a}^7	α_{1A}^{15}	$\alpha_{1A}^{15,18,19,26-29}$
		$\alpha_{1a} > \alpha_{1d}^{8-11}$	$\alpha_{1A}, \alpha_{1B}^{16}$	$\alpha_{1L}^{15,17,30}$
	Rat	$\alpha_{1a} > \alpha_{1b} > \alpha_{1d}^{31}$	$\alpha_{1A}, \alpha_{1L}^{17}$	α_{1L}^{33}
Bladder neck	Rabbit		α_{1A}^{15}	$\alpha_{1A}^{15,34}$ $\alpha_{1L}^{25,35}$
	Human	$\alpha_{1a} > \alpha_{1d}^{32}$		α_{1L}^{36}
	Rat	$\alpha_{1a} > \alpha_{1d} > \alpha_{1b}^{1,37,38}$	$\alpha_{1A}^{18,38}$	$\alpha_{1A}^{33,41}$
	Rabbit			$\alpha_{1A}^{18,34}$
				$\alpha_{1L}^{25,35,42,43}$
	Human	$\alpha_{1d} > \alpha_{1a}^{37}$	$\alpha_{1D} > \alpha_{1A}^{35}$	α_{1A}^{18}
		$\alpha_{1a}, \alpha_{1b}, \alpha_{1d}^{39}$	$\alpha_{1A}, \alpha_{1B}, \alpha_{1D}^{40}$	α_{1L}^{36}

mRNA: subtypes identified from RT-PCR studies or RNase protection assays.

Binding: subtypes detected by radioligand binding assay with tissue homogenates or membrane preparations, but in References 14 and 17, tissue segments were also used in binding assay.

Function: data obtained from bioassay where the contractile responses to noradrenaline or other α_1 -agonists were examined.

According to the standard nomenclature (Alexander *et al.*, 2011), the term α_{1A} is used to refer to receptor subtype. In this review, we will use the term only for receptor phenotype in order to focus on phenotypic variation (α_{1A} or α_{1L}) arising from the same gene (*ADRA1A*). To refer to receptor polypeptide, we instead use the term α_{1a} .

The superscripted numbers refer to the relevant reference and are shown here in short form; the full form is provided in the usual list of references below.

1. Scofield *et al.* (1995); 2. Walden *et al.* (1997); 3. Rokosh *et al.* (1994); 4. Homma *et al.* (2000); 5. Foster *et al.* (2004); 6. Piao *et al.* (2000); 7. Hirasawa *et al.* (1993); 8. Price *et al.* (1993); 9. Faure *et al.* (1994); 10. Tseng-Crank *et al.* (1995); 11. Nasu *et al.* (1996); 12. Yazawa and Honda (1993); 13. Hiraoka *et al.* (1999); 14. Su *et al.* (2008); 15. Testa *et al.* (1993); 16. Michel *et al.* (1996); 17. Morishima *et al.* (2007); 18. Chang *et al.* (2000); 19. Lagu *et al.* (2000); 20. Honda *et al.* (1985); 21. Delafloite *et al.* (1996); 22. Yamagishi *et al.* (1996); 23. Hiraoka *et al.* (1995); 24. Leonardi *et al.* (1997); 25. Van der Graaf *et al.* (1997); 26. Forray *et al.* (1994); 27. Marshall *et al.* (1995); 28. Chess-Williams *et al.* (1996); 29. Eltze *et al.* (2001); 30. Ford *et al.* (1996); 31. Yono *et al.* (2004); 32. Nasu *et al.* (1998); 33. Muramatsu *et al.* (unpublished observation); 34. Honda and Nakagawa (1986); 35. Deplanne and Galzin (1996); 36. Taki *et al.* (1999); 37. Malloy *et al.* (1998); 38. Hampel *et al.* (2002); 39. Nomiya and Yamaguchi (2003); 40. Levin *et al.* (1988); 41. Lluet *et al.* (2003); 42. Kava *et al.* (1998); 43. Williams *et al.* (1999).

Table 2 α_1 -Adrenoceptor subtypes and their pharmacological characterization

Gene	Receptor polypeptide	Phenotype	Affinity (mean pK _B)		Tamsulosin	RS-17053
			Prazosin	Silodosin		
ADRA1A	α _{1a}	α _{1A}	9.6	9.8	10.0	8.7
		α _{1L}	8.0	9.8	10.0	6.3
ADRA1B	α _{1b}	α _{1B}	10.2	8.0	9.3	7.8
ADRA1D	α _{1d}	α _{1D}	10.0	8.4	9.9	7.8

Affinity values are from Morishima *et al.* (2007).

2006). Interestingly, however, the α_{1a} -adrenoceptor mRNA detected at the tissue level disappears in cultures of human prostatic smooth muscle cells, in contrast to the consistent expression of α_{1b} - and α_{1d} -adrenoceptor mRNAs (Boesch *et al.*,

1999). The relative expression of α_{1a} -adrenoceptor mRNA in the lower urinary tract of humans has also been examined by *in situ* hybridization studies. In the human prostate, α_{1a} -adrenoceptor mRNA was mainly detected in the stroma,

including smooth muscle cells, but not in the glandular epithelium (Walden *et al.*, 1999).

Data regarding the expression of α_1 -adrenoceptor mRNA in the human bladder are inconsistent, but it appears that the expression of α_1 -adrenoceptor mRNA is extremely low in the bladder (Malloy *et al.*, 1998; Nomiya and Yamaguchi, 2003). In the human detrusor, β (mainly β_3)-adrenoceptors are dominant over α -adrenoceptors, based on the fact that the normal response to noradrenaline is relaxation rather than contraction (Andersson, 1993). Therefore, we can conclude that the functional significance of α -adrenoceptors in the detrusor contraction may be marginal or non-existent (Fig. 1). On the other hand, the density of noradrenergic nerves increases markedly towards the bladder neck, where the smooth muscle receives a dense noradrenergic nerve supply (Gosling *et al.*, 1999). In the human bladder, the predominant expression of α_{1A} -adrenoceptor mRNA in the dome, trigone and base has also been reported (Walden *et al.*, 1997).

Thus, the mRNA data in human urinary tract indicate that the α_{1A} -adrenoceptor polypeptide is a potential target for pharmacotherapy in patients with BPH and SUL.

α_1 -Adrenoceptor pharmacological anomalies in the lower urinary tract

The classical α_1 -adrenoceptors (α_{1A} , α_{1B} and α_{1D}) show high affinity for prazosin (pK_i or $pK_B > 9$) in most binding and functional studies (Lomasney *et al.*, 1991; Hieble *et al.*, 1995; Ford *et al.*, 1996; Theroux *et al.*, 1996; Taniguchi *et al.*, 1999; Suzuki *et al.*, 2000; Israilova *et al.*, 2004) (Table 2). However, the functional α_1 -adrenoceptors identified in the lower urinary tract are known to be relatively resistant to prazosin (Muramatsu *et al.*, 2009) ($pK_B = \sim 8$) (Table 1). Thus, this pharmacological anomaly, despite the predominance of α_{1A} -adrenoceptor mRNA, caused confusion about the α_1 -adrenoceptor subtypes in the lower urinary tract. Because different affinities for antagonists have traditionally been regarded as characteristic pharmacological criteria for defining novel receptors (Kenakin, 1995; Rang, 2006), the anomalous α_1 -adrenoceptor showing low affinity for prazosin suggests the existence of a distinctive subtype (or phenotype).

Pharmacological heterogeneity of α_1 -adrenoceptors was originally reported by Drew (1985), who first noted a wide variation in the functional affinities for yohimbine and prazosin. This evidence was confirmed in experiments with isolated blood vessels by Flavahan and Vanhoutte (1986), and they proposed two distinct α_1 -adrenoceptor subtypes that could be distinguished by their different affinities for both prazosin and yohimbine (α_{1H} and α_{1L} according to their High or Low affinity for prazosin). This subclassification was subsequently extended by many pharmacologists and in many tissues including the lower urinary tract (Muramatsu *et al.*, 1990; 1991; 1995; Ford *et al.*, 1996; Testa *et al.*, 1997; Stam *et al.*, 1999; Argyle and McGrath, 2000). In this subclassification, the classical α_{1A} -, α_{1B} - and α_{1D} -adrenoceptors are included in the α_{1H} group, and the anomalous α_1 -adrenoceptor showing low affinity for prazosin in the lower urinary tract has been reported as the α_{1L} -adrenoceptor (Muramatsu *et al.*, 1991; 1995; Ford *et al.*, 1996; Langer, 1999;

Nishimune *et al.*, 2010a). Antagonistic potencies against noradrenaline-induced contractions in rat, rabbit and human prostate are low for prazosin ($pK_B = \sim 8$) and α_{1A} -antagonists (5-methylurapidil, WB4101, RS-17053), but are high for silodosin and tamsulosin (Hiraoka *et al.*, 1995; 1999; Ford *et al.*, 1996; Leonardi *et al.*, 1997; Testa *et al.*, 1997; Van der Graaf *et al.*, 1997; Morishima *et al.*, 2007; Su *et al.*, 2008). In contrast to this nomenclature, α_1 -adrenoceptors in the lower urinary tract have been also named as α_{1A} -adrenoceptors in many reports (Table 1). Therefore, there has been confusion in defining the functional α_1 -adrenoceptor in the lower urinary tract (Table 1), which may in part depend on distinct subclassifications (α_{1H} , α_{1L} vs. α_{1A} , α_{1B} , α_{1D}).

α_2 -Adrenoceptor can also be detected at the mRNA and protein levels in urogenital tissues (Yablonsky *et al.*, 1986; Michel and Vrydag, 2006). Therefore, the anomalous characteristics of adrenergic contractions in the lower urinary tract may be associated with the α_2 -adrenoceptor. In fact, clonidine (α_2 -agonist) can produce a significant contraction in the female rabbit urethra (Larsson *et al.*, 1986). However, clonidine is inactive in the isolated female human urethra, while noradrenaline produces contractions through sites with low affinity for prazosin (Taki *et al.*, 1999). These results show that the α_2 -adrenoceptor is not significantly involved in the anomalous contraction in the human urethra (Ruffolo and Hieble, 1999), although there may be relevant species differences in this adrenoceptor.

Identification of α_1 -adrenoceptors by radioligand binding assay

Because reliable subtype-specific α_{1A} -adrenoceptor antibodies were recently reported to be unavailable (Jensen *et al.*, 2009), investigation of α_1 -adrenoceptors at the protein level are herein summarized from radioligand-binding experiments.

Binding assay with membrane homogenates

Specific binding of [3 H]-prazosin, [125 I]-HEAT, [3 H]-tamsulosin and [3 H]-silodosin to α_1 -adrenoceptors in membrane preparations of the lower urinary tract has been detected, with the density of binding in the order, prostate > urethra > bladder. In the rat, rabbit and human prostate, the most abundant α_1 -adrenoceptor is the α_{1A} -subtype, which has been identified as having high affinity for prazosin, tamsulosin, silodosin and other α_{1A} -selective antagonists (5-methylurapidil and RS-17053) (Tables 1 and 2). Thus, low-affinity sites for prazosin (α_{1L} -adrenoceptors) are not detected in the membrane preparations of lower urinary tract tissues and at subnanomolar concentrations of [3 H]-prazosin. The high abundance of the binding sites showing α_{1A} -adrenoceptor profile in the lower urinary tract is in agreement with the mRNA expression data mentioned above.

Three α_1 -adrenoceptor cDNAs (including splice variants of α_{1A} -adrenoceptors) were transfected in several cell lines (CHO cells, COS-7 cells, HEK293 cells, HeLa cells) and the pharmacological binding characteristics in the membrane preparations were compared with those in native tissues. The three recombinant α_1 -adrenoceptors showed high (subnanomolar) affinity for prazosin (Table 2). The cloned α_{1A} -

adrenoceptor and its splice variants showed the same pharmacological profile as that recognized in the membrane preparations of lower urinary tract (Lomasney *et al.*, 1991; Theroux *et al.*, 1996; Piao *et al.*, 2000; Suzuki *et al.*, 2000; Ramsay *et al.*, 2004).

Binding assay with whole cells and intact tissues

Most radioligand-binding studies conducted to date have involved homogenates or membrane preparations of tissues or cells as a source of receptors. Because tissue/cell homogenization physically disturbs the receptor micro-environment, it may cause changes in some of the pharmacological characteristics of the receptor. Therefore, in order to retain the natural/native receptor conformation by minimizing physical agitation, whole cells or intact tissue segments must be used in binding assays.

Ford and co-workers reported that the pharmacological characteristics of the recombinant α_{1A} -adrenoceptor can vary substantially depending upon assay conditions (Ford *et al.*, 1997; Daniels *et al.*, 1999). In CHO cells expressing the recombinant α_{1A} -adrenoceptor, prazosin and RS-17053 (α_{1A} -selective antagonist) show substantially lower potency against functional responses (phosphatidyl inositol turnover and calcium influx) in intact cells than inhibition of radioligand binding to α_{1A} -adrenoceptors in membrane homogenates. Furthermore, the K_i values for prazosin and RS-17053 as competitive inhibitors of [3 H]-prazosin binding to α_{1A} -adrenoceptors in these CHO cells are dependent on assay conditions, with lower affinity observed when binding is conducted under more physiological conditions (culture medium, intact cells, 37°C) than under conditions commonly employed for radioligand binding assays (artificial buffer, membrane homogenates, 20°C). These observations have led to the proposal that the α_{1L} -adrenoceptor may not represent an independent molecular entity, but rather may be an 'affinity state' of the α_{1A} -adrenoceptor that is predominant in lower urinary tract.

Recently, a tissue segment binding method was developed and applied to numerous tissues (Tanaka *et al.*, 2004; Muramatsu *et al.*, 2005). In this method, tissue segments are incubated (without homogenization) in a nutrient medium such as Krebs solution during the course of ligand binding. To identify the α_1 -adrenoceptors having low affinity for prazosin, [3 H]-silodosin was used instead of [3 H]-prazosin, because [3 H]-prazosin at subnanomolar concentrations cannot bind sufficiently to α_{1L} -adrenoceptors (Su *et al.*, 2008; Muramatsu *et al.*, 2009). Silodosin and its tritiated radioligand are known to be of equally high affinity for both the α_{1A} - and α_{1L} -adrenoceptors (Murata *et al.*, 1999; Su *et al.*, 2008) (Table 2).

In segments of human, mouse and rabbit prostate, the binding of [3 H]-silodosin was biphasically displaced by prazosin, indicating the coexistence of high and low-affinity sites for prazosin, which correspond to α_{1A} - and α_{1L} -adrenoceptors (Morishima *et al.*, 2007; Muramatsu *et al.*, 2008; Su *et al.*, 2008). This result is very different from the results obtained in homogenates, in which a single high-affinity site for prazosin (α_{1A} -adrenoceptor) was detected. The low-affinity site for prazosin in the prostate segments also showed low affinity for some α_{1A} -selective antagonists (RS-

17053, 5-methylurapidil), but tamsulosin (which has high affinity for α_{1A} -, α_{1L} - and α_{1D} -subtypes) did not discriminate either the high- or low-affinity sites for prazosin. Similar results were obtained in studies of other tissues in which the α_{1L} -adrenoceptor was identified as a functional receptor (Hiraizumi-Hiraoka *et al.*, 2004; Morishima *et al.*, 2008; Muramatsu *et al.*, 2008; 2009). From these observations, it was suggested that α_{1L} -adrenoceptors (or α_{1L} -phenotype) coexist with α_{1A} -adrenoceptors (or α_{1A} -phenotype) as pharmacologically distinct entities under intact segment conditions, whereas the pharmacological profile of α_{1L} -adrenoceptors converts to the α_{1A} -phenotype upon homogenization.

More recently, this conclusion was again confirmed in a recombinant system (Nishimune *et al.*, 2010b). In the CHO cell line, transfection of α_{1A} -adrenoceptor cDNA predominantly expresses α_{1A} -adrenoceptor phenotype, with an extremely minor proportion of α_{1L} -adrenoceptor (less than 10% of total α_1 -adrenoceptor). However, persistent over-expression of the protein, cysteine-rich epidermal growth factor-like domain 1 α (CRELD1 α), which was found as a potential α_{1A} -adrenoceptor-interacting protein candidate) strongly reduced the population of α_{1A} -adrenoceptor phenotype in CHO cells (Nishimune *et al.*, 2010b). Although mechanisms underlying the interactions between generation of CRELD1 α and α_{1A} -adrenoceptors and α_{1L} -adrenoceptors remain unclear, two distinct (α_{1L} -adrenoceptor-dominant and α_{1A} -adrenoceptor-dominant) CHO cell lines were eventually established. Under whole-cell conditions, in contrast to the α_{1A} -adrenoceptor, pharmacological and functional properties of the established α_{1L} -adrenoceptor show low affinity for prazosin and other α_{1A} -adrenoceptor antagonists (5-methylurapidil, RS-17053), and the agonist and antagonist pharmacology is consistent with the profile of the α_{1L} -adrenoceptor identified in the lower urinary tract. Therefore, from these lines of evidence, it may be now concluded that the α_{1L} -adrenoceptor is one of the α_{1A} -adrenoceptor gene products and occurs as an entity distinct from the α_{1A} -adrenoceptor phenotype under conditions when the tissue/cell is kept intact. This conclusion would also explain why α_{1L} -adrenoceptors could not be detected after homogenization but are easily recognized in functional bioassay studies with intact tissue strips (Muramatsu *et al.*, 2009).

Identification of the gene encoding α_{1L} -adrenoceptor

Despite extensive searches at early stages after the proposal of the α_{1L} -adrenoceptor and the subsequent completion of the human genome sequencing project, a distinct gene for the proposed α_{1L} -adrenoceptor has not been identified. Rather, as described above, a close relationship between α_{1L} -adrenoceptor and α_{1A} -adrenoceptor has been considered (Ford *et al.*, 1997; Hiraizumi-Hiraoka *et al.*, 2004; Morishima *et al.*, 2008).

In order to explore this possible link between α_{1A} - and α_{1L} -adrenoceptors, we analysed *in vivo* phenotypes of mice having disrupted alleles of the classical α_1 -adrenoceptors (α_{1A} , α_{1B} and α_{1D}) (Muramatsu *et al.*, 2008). The integrity of the α_{1L} -adrenoceptors were confirmed both in terms of ligand

binding properties and contractile function in the *Adra1B*^{-/-} (α_{1b} ^{-/-}) and *Adra1D*^{-/-} (α_{1d} ^{-/-}) mice as well as in the wild-type mice. In contrast, both α_{1L} - and α_{1A} -adrenoceptors were completely absent from the *Adra1A*^{-/-} (α_{1a} ^{-/-}) mice. These results unequivocally demonstrate that both α_{1A} -adrenoceptors and α_{1L} -adrenoceptors are derived from the same *Adra1A* (α_{1a}) gene (Gray *et al.*, 2008; Muramatsu *et al.*, 2008) (Table 2).

Observation of α_{1L} -adrenoceptor distribution by fluorescent probe

Alexa Fluor 488 dye conjugated with silodosin (Alexa-488-silodosin) was recently introduced as a fluorescent probe (Morishima *et al.*, 2010). Alexa-488-silodosin retains the high affinity and selectivity for α_{1A} - and α_{1L} -adrenoceptors as shown by unlabelled silodosin. Histochemical experiments with this fluorescent probe clearly showed that Alexa-488-silodosin binds to the smooth muscle but not the glandular tissue in the human prostate, and that the binding is resistant to low concentrations of prazosin. These results are in good agreement with *in situ* hybridization data showing selective expression of α_{1A} -adrenoceptor mRNA in the stroma of the human prostate (Walden *et al.*, 1999). As the Alexa-488-silodosin can specifically label α_{1L} -adrenoceptors, particularly by co-incubation with low concentrations of prazosin (to mask the α_{1A} -adrenoceptor), this novel molecular probe provides a versatile tool to study α_{1L} -adrenoceptor histochemically (Morishima *et al.*, 2010).

Perspective

As mentioned above, recent progress in this field clearly demonstrates that two distinct α_1 -adrenoceptor phenotypes (α_{1A} and α_{1L}) originate from a single α_{1a} -adrenoceptor gene and coexist in some tissues. However, adrenergic contraction in the lower urinary tract is predominantly mediated through α_{1L} -, but not α_{1A} -adrenoceptors (Fig. 1). In general, the affinity values (pKi or pK_B) for prazosin for α_{1L} -adrenoceptors are around 8, but recent studies reveal a further variation in prazosin affinity (pKi or pK_B = 6.3–8.5) at various α_{1L} -adrenoceptors in many tissues and species (Muramatsu *et al.*, 2009). This is reminiscent of the original question on α_1 -adrenoceptors (Drew, 1985), suggesting further heterogeneity in α_{1L} -adrenoceptor pharmacology. At present, the mechanisms underlying the expression of α_{1L} -adrenoceptor phenotype and its functional predominance in several tissues remain unknown. However, it is likely that the expression of divergent α_{1L} -adrenoceptor phenotypes is strongly dependent on any modification of the tissues of various species, rather than a simple variation of the α_{1a} -adrenoceptor protein or additional subtypes (Muramatsu *et al.*, 2009; Nishimune *et al.*, 2010a).

Recently, ample evidence has been accumulating suggesting that antagonist affinity is not necessarily constant at a given receptor expressed in different tissues/cells and examined under different assay conditions (Kenakin, 2003; Baker and Hill, 2007; Nelson and Challiss, 2007; Muramatsu *et al.*, 2008). The α_{1L} -adrenoceptor exemplifies this type of variable

affinity, as after homogenization, the phenotype changed from α_{1L} into α_{1A} . It is likely that tissue integrity is an important factor to determine receptor properties (Su *et al.*, 2008; Muramatsu *et al.*, 2009). Therefore, we may have to re-evaluate pharmacodynamic and pharmacokinetic effects of currently used drugs, and to reconstruct drug development strategies. Now, α_1 -antagonists, such as tamsulosin, silodosin, alfuzosin, are clinically used in BPH patients. According to the evidence mentioned above, these antagonists appear to act mainly on functional α_{1L} -adrenoceptors in the lower urinary tract, but are not specific for the α_{1L} -adrenoceptor. The α_{1L} -adrenoceptors in the female urethra may be a new target in therapy for SUI. For this purpose, two α_1 -adrenoceptor agonists (NS-49 and Ro 115-1240) have been developed. However, these compounds are full agonists of the α_{1A} -adrenoceptor or partial agonists of the $\alpha_{1A/L}$ -adrenoceptor (Obika *et al.*, 1995; Blue *et al.*, 2004; Musselman *et al.*, 2004). Thus, more selective or specific drugs against α_{1L} -adrenoceptors may lead to improved uroselectivity.

Conclusion

Since the successful cloning of most receptors, it has become possible to elucidate numerous physiological responses by genome-based subtype (genotypes). However, there are still some unique phenotypes showing distinct pharmacology in native tissues. The α_{1L} -adrenoceptor is representative of this group, and originates from the α_{1a} -adrenoceptor gene together with the α_{1A} -adrenoceptor phenotype. In this review, we propose that different phenotypes are expressed from a single gene in native tissues ('one gene-multiple phenotypes theory'), which may explain the long controversy regarding some putative receptors, such as α_{1L} -adrenoceptor in the lower urinary tract, and further highlights phenotype-dependent pharmacology ('phenotype pharmacology').

Acknowledgements

This work was supported in part by a Grant-in Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS); by the Adaptable and Seamless Technology Transfer Program through target-driven R&D from the Japan Science and Technology Agency (JST); and by a grant from the Smoking Research Foundation of Japan. Anisuzzaman ASM was supported by the Headquarters for the Advancement of High Priority Research Grant, Fukui University.

Conflict of interest

The authors declare no competing financial interests.

References

- Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD *et al.* (2006). Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. *Br J Pharmacol* 148: 565–578.

- Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1–S324.
- Andersson KE (1993). Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45: 253–308.
- Andersson KE (2002). Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 19: 390–396.
- Andersson KE, Wein AJ (2004). Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 56: 581–631.
- Argyle SA, McGrath JC (2000). An α_{1A} / α_{1L} -adrenoceptor mediates contraction of canine subcutaneous resistance arteries. J Pharmacol Exp Ther 295: 627–633.
- Baker JG, Hill SJ (2007). Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 28: 374–381.
- Blue DR, Daniels DV, Gever JR, Jett MF, O'yang C, Tang HM *et al.* (2004). Pharmacological characteristics of Ro 115–1240, a selective $\alpha_{1A/1L}$ -adrenoceptor agonist: a potential therapy of stress urinary incontinence. BJU Int 93: 162–170.
- Boesch ST, Corvin S, Zhang J, Rogatsch H, Bartsch G, Klocker H (1999). Modulation of the differentiation status of cultured prostatic smooth muscle cells by an α_1 -adrenergic receptor antagonist. Prostate 39: 226–233.
- Chang RS, Chen TB, O'malley SS, Pettibone DJ, Disalvo J, Francis B *et al.* (2000). In vitro studies on L-771, 688 (SNAP 6383), a new potent and selective α_{1A} -adrenoceptor antagonist. Eur J Pharmacol 409: 301–312.
- Chapple CR (2001). Alpha adrenoceptor antagonists in the year 2000: is there anything new? Curr Opin Urol 11: 9–16.
- Chess-Williams R, Chapple CR, Verfurth F, Noble AJ, Couldwell CJ, Michel MC (1996). The effects of SB 216469, an antagonist which discriminates between the α_{1A} -adrenoceptor and the human prostatic α_1 -adrenoceptor. Br J Pharmacol 119: 1093–1100.
- Cooper KL, McKiernan JM, Kaplan SA (1999). Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57: 9–17.
- Daniels DV, Gever JR, Jasper JR, Kava MS, Lesnick JD, Meloy TD *et al.* (1999). Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. Eur J Pharmacol 370: 337–343.
- Delafotte S, Auguet M, Chabrier PE (1996). Pharmacological evidence that different α_1 adrenoceptor subtypes mediate contraction in rabbit prostate and hypogastric artery. Acta Physiol Scand 158: 241–251.
- Deplanne V, Galzin AM (1996). Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther 278: 527–534.
- Drew GM (1985). What do antagonists tell us about α_1 -adrenoceptors? Clin Sci 68 (Suppl. 10): 15s–19s.
- Eltze M, Bper R, Michel MC, Hein P, Testa R, Ulrich WR *et al.* (2001). In vitro and in vivo uroselectivity of B8805–033, an antagonist with high affinity at prostatic α_{1A} - vs α_{1B} - and α_{1D} -adrenoceptors. Naunyn Schmiedeberg Arch Pharmacol 363: 649–662.
- Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D (1994). Identification of α_1 -adrenoceptor subtypes present in the human prostate. Life Sci 54: 1595–1605.
- Flavahan NA, Vanhoutte PM (1986). α_1 -Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol Sci 7: 347–349.
- Ford AP, Arredondo NF, Blue DR Jr, Bonhaus DW, Jasper J, Kava MS *et al.* (1996). RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 49: 209–215.
- Ford AP, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD *et al.* (1997). Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br J Pharmacol 121: 1127–1135.
- Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R *et al.* (1994). The α_1 -adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α_{1C} subtype. Mol Pharmacol 45: 703–708.
- Foster HE Jr, Yono M, Shin D, Takahashi W, Pouresmail M, Afiatpour P *et al.* (2004). Effects of chronic administration of doxazosin on α_1 -adrenoceptors in the rat prostate. J Urol 172: 2465–2470.
- Gosling JA, Dixon JS, Jen PYP (1999). The distribution of noradrenergic nerves in the human lower urinary tract. Eur Urol 38 (Suppl. 1): 23–30.
- Gray K, Short J, Ventura S (2008). The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155: 103–109.
- Hampel C, Dolber PC, Smith MP, Savic DL, Thuroff JW, Thor KB *et al.* (2002). Modulation of bladder α_1 -adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167: 1513–1521.
- Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ *et al.* (1995). International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 47: 267–270.
- Hiraizumi-Hiraoka Y, Tanaka T, Yamamoto H, Suzuki F, Muramatsu I (2004). Identification of alpha-1L adrenoceptor in rabbit ear artery. J Pharmacol Exp Ther 310: 995–1002.
- Hiraoka Y, Ohmura T, Sakamoto S, Hayashi H, Muramatsu I (1995). Identification of α_1 -adrenoceptor subtypes in the rabbit prostate. J Auton Pharmacol 15: 271–278.
- Hiraoka Y, Ohmura T, Oshita M, Watanabe Y, Morikawa K, Nagata O *et al.* (1999). Binding and functional characterization of α_1 -adrenoceptor subtypes in the rat prostate. Eur J Pharmacol 366: 119–126.
- Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J *et al.* (1993). Cloning, functional expression and tissue distribution of human cDNA for the α_{1C} -adrenergic receptor. Biochem Biophys Res Commun 195: 902–909.
- Homma Y, Hamada K, Nakayama Y, Tsujimoto G, Kawabe K (2000). Effect of castration on contraction and α_1 -adrenoceptor expression in rat prostate. Br J Pharmacol 131: 1454–1460.
- Honda K, Nakagawa C (1986). Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 239: 512–516.
- Honda K, Miyata-Osawa A, Takenaka T (1985). α_1 -Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmiedeberg Arch Pharmacol 330: 16–21.

- Israilova M, Tanaka T, Suzuki F, Morishima S, Muramatsu I (2004). Pharmacological characterization and cross talk of α_{1A} - and α_{1B} -adrenoceptors coexpressed in human embryonic kidney 293 cells. *J Pharmacol Exp Ther* 309: 259–266.
- Jensen BC, Swigart PM, Simpson PC (2009). Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. *Naunyn Schmiedeberg Arch Pharmacol* 379: 409–412.
- Kava MS, Blue DR Jr, Vimont RL, Clarke DE, Ford AP (1998). α_{1L} -Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. *Br J Pharmacol* 123: 1359–1366.
- Kenakin T (1995). On the importance of the 'antagonist assumption' to how receptors express themselves. *Biochem Pharmacol* 50: 17–26.
- Kenakin T (2003). Predicting therapeutic value in the lead optimization phase of drug discovery. *Nat Rev Drug Discov* 2: 429–438.
- Lagu B, Tian D, Jeon Y, Li C, Wetzel JM, Nagarathnam D *et al.* (2000). De novo design of a novel oxazolidinone analogue as a potent and selective α_{1A} adrenergic receptor antagonist with high oral bioavailability. *J Med Chem* 43: 2775–2778.
- Langer SZ (1999). History and nomenclature of α_1 -adrenoceptors. *Eur Urol* 36 (Suppl. 1): 2–6.
- Larsson B, Sjogren C, Andersson KE (1986). Regional distribution of alpha-adrenoceptor subtypes in the female rabbit urethra. *Acta Physiol Scand* 126: 39–43.
- Lefevre-Borg F, O'Connor SE, Schoemaker H, Lechaire J, Gautier E *et al.* (1993). Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. *Br J Pharmacol* 109: 1282–1289.
- Leonardi A, Hieble JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G *et al.* (1997). Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. *J Pharmacol Exp Ther* 281: 1272–1283.
- Levin RM, Ruggieri MR, Wein AJ (1988). Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. *J Urol* 139: 844–848.
- Lluel P, Palea S, Ribière P, Barras M, Teillet L, Corman B (2003). Increased adrenergic contractility and decreased mRNA expression of NOS III in aging rat urinary bladders. *Fundam Clin Pharmacol* 17: 633–641.
- Lomasney JW, Cotecchia S, Lefkowitz RJ, Caron MG (1991). Molecular biology of alpha-adrenergic receptors: implications for receptor classification and for structure-function relationships. *Biochim Biophys Acta* 1095: 127–139.
- Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL *et al.* (1998). α_1 -Adrenergic receptor subtypes in human detrusor. *J Urol* 160: 937–943.
- Marshall I, Burt RP, Chapple CR (1995). Noradrenaline contractions of human prostate mediated by α_{1A} - (α_{1c} -) adrenoceptor subtype. *Br J Pharmacol* 115: 781–786.
- Michel MC, Vrydag W (2006). α_1 -, α_2 - And β -adrenoceptors in the urinary bladder, urethra and prostate. *Br J Pharmacol* 147: S88–S119.
- Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D (1996). Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α_1 -adrenoceptor subtypes and in human prostate. *J Auton Pharmacol* 16: 21–28.
- Michelotti GA, Price DT, Schwinn DA (2000). Alpha-1 adrenergic receptor regulation: basic science and clinical implications. *Pharmacol Ther* 88: 281–309.
- Morishima S, Tanaka T, Yamamoto H, Suzuki F, Akino H, Yokoyama O *et al.* (2007). Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. *J Urol* 177: 377–381.
- Morishima S, Suzuki F, Yoshiki H, Anisuzzaman ASM, Sathi ZS, Tanaka T *et al.* (2008). Identification of alpha-1L adrenoceptor in rat cerebral cortex and possible relationship between alpha-1L and alpha-1A adrenoceptors. *Br J Pharmacol* 153: 1485–1494.
- Morishima S, Suzuki F, Nishimune A, Yoshiki H, Akino H, Yokoyama O *et al.* (2010). Visualization and tissue distribution of α_{1L} -adrenoceptor in human prostate by the fluorescently labeled ligand alexa-488-silodosin. *J Urol* 183: 812–819.
- Muramatsu I, Ohmura T, Kigoshi S, Hashimoto S, Oshita M (1990). Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. *Br J Pharmacol* 99: 197–201.
- Muramatsu I, Kigoshi S, Ohmura T (1991). Subtypes of α_1 -adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery. *Jpn J Pharmacol* 57: 535–544.
- Muramatsu I, Ohmura T, Hashimoto S, Oshita M (1995). Functional subclassification of vascular α_1 -adrenoceptors. *Pharmacol Commun* 6: 23–28.
- Muramatsu I, Tanaka T, Suzuki F, Li Z, Hiraizumi-Hiraoka Y, Anisuzzaman AS *et al.* (2005). Quantifying receptor properties: the tissue segment binding method – a powerful tool for the pharmacome analysis of native receptors. *J Pharmacol Sci* 98: 331–339.
- Muramatsu I, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T *et al.* (2008). Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout. *Br J Pharmacol* 155: 1224–1234.
- Muramatsu I, Suzuki F, Nishimune A, Anisuzzaman AS, Yoshiki H, Su TH *et al.* (2009). Expression of distinct α_1 -adrenoceptor phenotypes in pigmented and albino rabbit iris. *Br J Pharmacol* 158: 354–360.
- Murata S, Taniguchi T, Muramatsu I (1999). Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. *Br J Pharmacol* 127: 19–26.
- Musselman DM, Ford AP, Gennevois DJ, Harvison ML, Laurent AL, Mokatri AS *et al.* (2004). A randomized crossover study to evaluate Ro 115–1240, a selective $\alpha_{1A/L}$ -adrenoceptor partial agonist in women with stress urinary incontinence. *BJU Int* 93: 78–83.
- Nasu K, Moriyama N, Kawabe K, Tsujimoto G, Murai M, Tanaka T *et al.* (1996). Quantification and distribution of α_1 -adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. *Br J Pharmacol* 119: 797–803.
- Nasu K, Moriyama N, Fukasawa R, Tsujimoto G, Tanaka T, Yano J *et al.* (1998). Quantification and distribution of α_1 -adrenoceptor subtype mRNAs in human proximal urethra. *Br J Pharmacol* 123: 1289–1293.
- Nelson CP, Challiss RA (2007). 'Phenotypic' pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. *Biochem Pharmacol* 73: 737–751.

- Nishimune A, Suzuki F, Yoshiki H, Morishima S, Muramatsu I (2010a). α_1 -Adrenoceptor pharmacome: α_{1L} -adrenoceptor and α_{17} -adrenoceptor in the lower urinary tract. *Int J Urol* 17: 31–37.
- Nishimune A, Suzuki F, Yoshiki H, Morishima S, Muramatsu I (2010b). Identification of Cysteine-rich epidermal growth factor-like domain 1 α (CRELD1 α) as a novel α_{17} -adrenoceptor-down-regulating protein and establishment of an α_{1L} -adrenoceptor-expressing cell line. *J Pharmacol Sci* 113: 169–181.
- Nomiya M, Yamaguchi O (2003). A quantitative analysis of mRNA expression of α_1 and β -adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. *J Urol* 170: 649–653.
- Obika A, Shibata A, Horie K, Foglar R, Kimura K, Tsujimoto G (1995). NS-49, a novel α_{1A} -adrenoceptor-selective agonist using recombinant human α_1 -adrenoceptors. *Eur J Pharmacol* 291: 327–334.
- Piao H, Taniguchi T, Nakamura S, Zhu J, Suzuki F, Mikami D *et al.* (2000). Cloning of rabbit α_{1b} -adrenoceptor and pharmacological comparison of α_{1A} -, α_{1b} - and α_{1D} -adrenoceptors in rabbit. *Eur J Pharmacol* 396: 9–17.
- Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ (1993). Identification, quantification, and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate. *J Urol* 150: 546–551.
- Ramsay D, Carr IC, Padian J, Lopez-Gimenez JF, Thurlow R, Fidock M *et al.* (2004). High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the alpha1L-adrenoceptor. *Mol Pharmacol* 66: 228–239.
- Rang HP (2006). The receptor concept: pharmacology's big idea. *Br J Pharmacol* 147: S9–S16.
- Rokosh DG, Bailey BA, Stewart AF, Karns LR, Long CS, Simpson PC (1994). Distribution of α_{1C} -adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with α_{1B} and α_{1D} . *Biochem Biophys Res Commun* 200: 1177–1184.
- Ruffolo R Jr, Hieble JP (1999). Adrenoceptor Pharmacology: urogenital applications. *Eur Urol* 36 (Suppl. 1): 17–22.
- Scofield MA, Liu F, Abel PW, Jeffries WB (1995). Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. *J Pharmacol Exp Ther* 275: 1035–1042.
- Stam WB, Van der Graaf PH, Saxena PR (1999). Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. *Br J Pharmacol* 127: 661–670.
- Su TH, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T *et al.* (2008). Native profiles of α_{1A} -adrenoceptor phenotypes in rabbit prostate. *Br J Pharmacol* 155: 906–912.
- Suzuki F, Taniguchi T, Takauji R, Murata S (2000). Splice isoforms of α_{1A} -adrenoceptor in rabbit. *Br J Pharmacol* 129: 1569–1576.
- Takeda M, Hatano A, Arai K, Obara K, Tsutsui T, Takahashi K (1999). Alpha1- and alpha 2-adrenoceptors in BPH. *Eur Urol* 36 (Suppl. 1): 31–34.
- Taki N, Taniguchi T, Okada K, Moriyama N, Muramatsu I (1999). Evidence for predominant mediation of α_1 -adrenoceptor in the tonus of entire urethra of women. *J Urol* 162: 1829–2832.
- Tanaka T, Zhang L, Suzuki F, Muramatsu I (2004). Alpha-1 adrenoceptors: evaluation of receptor subtype-binding kinetics in intact arterial tissues and comparison with membrane binding. *Br J Pharmacol* 141: 468–476.
- Taniguchi T, Inagaki R, Murata S, Akiba I, Muramatsu I (1999). Microphysiometric analysis of human α_{1A} -adrenoceptor expressed in Chinese hamster ovary cells. *Br J Pharmacol* 127: 962–968.
- Testa R, Guarneri L, Ibba M, Strada G, Poggesi E, Taddei C *et al.* (1993). Characterization of α_1 -adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. *Eur J Pharmacol* 249: 307–315.
- Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G *et al.* (1997). Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. *J Pharmacol Exp Ther* 281: 1284–1293.
- Theroux TL, Esbenshade TA, Minneman KP (1996). Coupling efficacies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors. *Mol Pharmacol* 50: 1376–1387.
- Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J *et al.* (1995). The α_{1C} -adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. *Br J Pharmacol* 115: 1475–1485.
- Van der Graaf PH, Deplanne V, Duquenne C, Angel I (1997). Analysis of α_1 -adrenoceptors in rabbit lower urinary tract and mesenteric artery. *Eur J Pharmacol* 327: 25–32.
- Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL (1997). Localization of mRNA and receptor binding sites for the alpha 1A-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. *J Urol* 157: 1032–1038.
- Walden PD, Gerardi C, Lepor H (1999). Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. *J Urol* 161: 635–640.
- Wess J, Eglen RM, Gautam D (2007). Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat Rev Drug Discov* 6: 721–733.
- Williams TJ, Blue DR, Daniels DV, Davis B, Elworthy T, Geber JR *et al.* (1999). In vitro α_1 -adrenoceptor pharmacology of Ro 70.0004 and RS-100329, novel α_{1A} -adrenoceptor selective antagonists. *Br J Pharmacol* 127: 252–258.
- Yablonsky F, Riffaund JP, Lacolle JY, Dausse JP (1986). Alpha 1- and alpha 2-adrenoceptors in the smooth muscle of male and female rabbit urethra. *Eur J Pharmacol* 11: 1–8.
- Yamagishi R, Akiyama K, Nakamura S, Hora M, Masuda N, Matsuzawa A *et al.* (1996). Effect of KMD-3213, an α_{1A} -adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. *Eur J Pharmacol* 315: 73–79.
- Yazawa H, Honda K (1993). α_1 -Adrenoceptor subtype in the rat prostate is preferentially the α_{1A} type. *Jpn J Pharmacol* 62: 297–304.
- Yono M, Foster HE Jr, Takahashi W, Pouresmail M, Latifpour J (2004). Doxazosin-induced up-regulation of α_{1A} -adrenoceptor mRNA in the rat lower urinary tract. *Can J Physiol Pharmacol* 82: 872–878.